Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Pharmaceutical Daily,
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort